Mesa Laboratories Inc

NASDAQ MLAB

Download Data

Mesa Laboratories Inc Price to Sales Ratio (P/S) on June 03, 2024: 2.35

Mesa Laboratories Inc Price to Sales Ratio (P/S) is 2.35 on June 03, 2024, a -25.50% change year over year. The price to sales ratio compares the market price per share of a company's stock to its sales revenue per share. It is calculated by dividing the market capitalization by the revenue, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's sales revenue. A higher ratio suggests that investors are willing to pay a higher price for each unit of sales revenue, indicating positive market sentiment and expectations for future revenue growth.
  • Mesa Laboratories Inc 52-week high Price to Sales Ratio (P/S) is 3.51 on August 31, 2023, which is 49.17% above the current Price to Sales Ratio (P/S).
  • Mesa Laboratories Inc 52-week low Price to Sales Ratio (P/S) is 2.13 on November 13, 2023, which is -9.72% below the current Price to Sales Ratio (P/S).
  • Mesa Laboratories Inc average Price to Sales Ratio (P/S) for the last 52 weeks is 2.76.
NASDAQ: MLAB

Mesa Laboratories Inc

CEO Mr. Gary M. Owens
IPO Date Jan. 25, 1995
Location United States
Headquarters 12100 West Sixth Avenue, Lakewood, CO, United States, 80228
Employees 698
Sector Technology
Industry Scientific & technical instruments
Description

Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. It operates in four segments: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions. The Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in various therapeutic areas, such as screenings for hereditary diseases, pharmacogenetics, and oncology related applications. The Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. The Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enable customers to automate chemical synthesis of peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The Calibration Solutions segment designs, manufactures, and markets quality control products to measure or calibrate temperature, pressure, pH, and humidity for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. The company was incorporated in 1982

Similar companies

ITRI

Itron Inc

NA

NA

FTV

Fortive Corp

NA

NA

ESE

ESCO Technologies Inc

NA

NA

ST

Sensata Technologies Holding NV

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email